ESR1 and breast cancer: In a similar study, dose-dependent inhibition of cell viability by 6.25–50 μg/mL (48 h) RE was seen in MDA-MB-231 (TN) and MCF-7 (ER+) breast cancer cells and MCF-7 cells had an IC50 of ~24.02 μg/mL.